Atypical Antipsychotics Falter In STEP-BD Study
This article was originally published in The Pink Sheet Daily
Study sponsored by National Institute of Mental Health suggests that newer drugs are not better than older ones for treatment of bipolar disorder.
You may also be interested in...
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Merger will create the leading generic injectable pharmaceutical company in the world.